Catia Traversari

Scopus Publications

Extracellular vesicles isolated from adipose tissue-derived mesenchymal stromal cells as carriers for Paclitaxel delivery
Angela Marcianti, Eleonora Spampinato, Sara Nava, Giulia Maria Stella, Paola Perego, Simona Pogliani, Simona Frigerio, Luca Mirra, Paola Gagni, Fabio Moda, Federico Angelo Cazzaniga, Giovanni Luca Beretta, Guido Maronati, Giuseppe Paglia, Angelo Guido Corsico, Catia Traversari, Daniela Lisini
Stem Cell Research and Therapy, 2025
BACKGROUND: Mesenchymal Stromal Cells (MSC)-derived Extracellular Vesicles (EV) represent innovative tools for drug delivery systems. However, their clinical use is limited by the lack of standardized good manufacturing practice (GMP)-compliant isolation and conservation protocols. In this study, we developed a GMP-compliant protocol for the preparation of MSC-EVs and investigated the feasibility of producing EVs loaded with paclitaxel (PTX) for clinical application as drug products. METHODS: Adipose tissues from 13 donors were used to obtain MSC-EVs via culture supernatant ultracentrifugation. EVs loaded with PTX were manufactured by adding the drug to the culture medium of MSCs before supernatant collection. EV identity was verified in terms of concentration/size, protein content, morphology, and expression of EV surface markers. The anti-proliferative activity, accumulation ability in tumor cells and PTX content, as well as their stability over time, were also evaluated. RESULTS: High numbers of EV/EV-PTX compliant in terms of integrity/identity were obtained and can be successfully stored for up to one year at -80 °C. Cellular studies have shown that EVs are capable of accumulating in tumor cells and, when loaded with PTX, inhibiting the proliferation of a pleural mesothelioma cell line. CONCLUSIONS: These results support the potential future clinical use of EVs as carriers for drug delivery to improve cancer treatment strategies.
Polyclonal expansion of functional tumor-reactive lymphocytes infiltrating glioblastoma for personalized cell therapy
Martina Maffezzini, Silvia Musio, Natalia Di Ianni, Agnese Rumolo, Monica Patanè, Andrea Galluzzo, Irene Sambruni, Arianna Berlendis, Domenico Aquino, Giacomo Baso, Manuela Zingarelli, Manuel Facciolla, Luisa Maddaloni, Rossella Valentino, Rosina Paterra, Fabio Agistri, Mariangela Farinotti, Luca Mattei, Paola Coluccia, Francesco Acerbi, Francesco DiMeco, Bianca Pollo, Antonio Silvani, Marica Eoli, Catia Traversari, Daniela Montagna, Serena Pellegatta
Nature Communications, 2025
Tumor-infiltrating lymphocyte (TIL)-therapy has received FDA approval for the treatment of advanced melanoma and shows potential for broader applications in solid tumors, including glioblastoma. In this study, tumor-reactive TILs (tr-TILs) are isolated and enriched for CD137 expression from cavitron ultrasonic aspirator (CUSA) emulsions of 161 adult patients diagnosed with diffuse gliomas. Tr-TILs are successfully expanded in 87 out of the 161 patients, reflecting an expansion rate of 54%. Notably, the presence of IDH1 mutation and the cumulative dose of steroids are identified as significant negative predictors of expansion efficacy. The expanded tr-TILs exhibit distinct phenotypic and molecular dysfunctional features yet show upregulated expression of progenitor/memory-like markers and polyclonal T-cell receptors. Importantly, these tr-TILs demonstrate specific antitumor reactivity against autologous tumor cells in both in vitro and in vivo xenograft models. These findings provide a compelling background for a personalized immunotherapeutic approach while tackling one of the most significant challenges in oncology. Tumor-infiltrating lymphocyte (TIL) therapy has demonstrated clinical benefit in patients with solid tumors. Here the authors propose a protocol for isolating and enriching TILs from cavitron ultrasonic aspirator emulsions of patients with glioma, showing the successful expansion of functional tumor-reactive TILs for personalized cell therapy.
Harnessing the reverse cholesterol transport pathway to favor differentiation of monocyte-derived APCs and antitumor responses
Laura Raccosta, Maura Marinozzi, Susan Costantini, Daniela Maggioni, Lorena Maria Ferreira, Gianfranca Corna, Paola Zordan, Angela Sorice, Diego Farinello, Silvia Bianchessi, Michela Riba, Dejan Lazarevic, Paolo Provero, Matthias Mack, Attilio Bondanza, Ivan Nalvarte, J-A Gustafsson, Valeria Ranzani, Francesco De Sanctis, Stefano Ugel, Silvère Baron, Jean-Marc A. Lobaccaro, Lorenzo Pontini, Manuela Pacciarini, Catia Traversari, Massimiliano Pagani, Vincenzo Bronte, Giovanni Sitia, Per Antonson, Andrea Brendolan, Alfredo Budillon, Vincenzo Russo
Cell Death and Disease, 2023
Lipid and cholesterol metabolism play a crucial role in tumor cell behavior and in shaping the tumor microenvironment. In particular, enzymatic and non-enzymatic cholesterol metabolism, and derived metabolites control dendritic cell (DC) functions, ultimately impacting tumor antigen presentation within and outside the tumor mass, dampening tumor immunity and immunotherapeutic attempts. The mechanisms accounting for such events remain largely to be defined. Here we perturbed (oxy)sterol metabolism genetically and pharmacologically and analyzed the tumor lipidome landscape in relation to the tumor-infiltrating immune cells. We report that perturbing the lipidome of tumor microenvironment by the expression of sulfotransferase 2B1b crucial in cholesterol and oxysterol sulfate synthesis, favored intratumoral representation of monocyte-derived antigen-presenting cells, including monocyte-DCs. We also found that treating mice with a newly developed antagonist of the oxysterol receptors Liver X Receptors (LXRs), promoted intratumoral monocyte-DC differentiation, delayed tumor growth and synergized with anti-PD-1 immunotherapy and adoptive T cell therapy. Of note, looking at LXR/cholesterol gene signature in melanoma patients treated with anti-PD-1-based immunotherapy predicted diverse clinical outcomes. Indeed, patients whose tumors were poorly infiltrated by monocytes/macrophages expressing LXR target genes showed improved survival over the course of therapy. Thus, our data support a role for (oxy)sterol metabolism in shaping monocyte-to-DC differentiation, and in tumor antigen presentation critical for responsiveness to immunotherapy. The identification of a new LXR antagonist opens new treatment avenues for cancer patients.
Characterization and functional analysis of CD44v6.CAR T cells endowed with a new low-affinity nerve growth factor receptor-based spacer
Anna Stornaiuolo, Barbara Valentinis, Camilla Sirini, Cinzia Scavullo, Claudia Asperti, Dan Zhou, Yeny Martinez De La Torre, Stefano Corna, Monica Casucci, Simona Porcellini, Catia Traversari
Human Gene Therapy, 2021
Effectiveness of adoptively transferred chimeric antigen receptor (CAR) T cells strongly depends on the quality of CAR-mediated interaction of the effector cells with the target antigen on tumor cells. A major role in this interaction is played by the affinity of the single-chain variable fragment (scFv) for the antigen, and by the CAR design. In particular, the spacer domain may impact on the CAR T cell function by affecting the length and flexibility of the resulting CAR. This study addresses the need to improve the manufacturing process and the antitumor activity of CD44v6-specific CAR T cells by defining the optimal structure of a spacer region derived from the extracellular domain of the human low-affinity nerve growth factor receptor (LNGFR). We tailored the LNGFR spacer to modulate CAR length to efficiently recognize distal or proximal epitopes and to allow selection of transduced CAR T cells by the use of clinical-grade validated manufacturing systems. The different LNGFR spacers investigated in this study are responsible for the generation of CAR T cells with a different memory phenotype, which is mainly related to the level of CAR expression and the extent of the associated tonic signaling. In particular, the CD44v6-NWN2.CAR T cells are enriched in central memory cells and show improved in vitro functions in terms of killing capability, and in vivo antitumor activity against hematological and solid tumors. Clinical Trial Registration numbers: clinicaltrial.gov NCT04097301; ClinicalTrials.gov, NCT00423124.
CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice
Simona Porcellini, Claudia Asperti, Stefano Corna, Eleonora Cicoria, Veronica Valtolina, Anna Stornaiuolo, Barbara Valentinis, Claudio Bordignon, Catia Traversari
Frontiers in Immunology, 2020
The main challenge of adoptive therapy with Chimeric Antigen Receptor modified T cells (CAR T) is the application to the field of solid tumors, where the identification of a proper antigen has emerged as one of the major drawbacks to CAR T cell treatment success. CD44 is a glycoprotein involved in cell-cell and cell-matrix interactions. The isoform containing the variant domain 6 of CD44 gene (CD44v6) has been implicated in tumorigenesis, tumor cell invasion and metastasis and represents an attractive target for CAR T cell therapies. Targeting CD44v6 antigen has been shown to control tumor growth in acute myeloid leukemia and multiple myeloma mouse models. While CAR T approach for the treatment of B cell malignancies has shown great success, response rates among patients with solid cancer are less favorable. The purpose of our study was to test the efficacy of CD44v6.CAR T cells, produced in compliance with Good Manufacturing Practice (GMP), in adenocarcinoma tumor models. We generated a bicistronic retroviral vector containing the CD44v6 CAR and the HSV-TK Mut2 suicide gene to enhance the safety of the proposed CAR T cell therapy. CD44v6 transduced CAR T cells were homogeneously positive for ΔLNGFR selection marker, were enriched in T central memory (TCM) and T memory stem cells (TSCM) and displayed a highly activated phenotype. In vitro assays revealed antigen-specific activation and cytotoxicity of human CD44v6.CAR T cells against CD44v6 expressing tumor cell lines. When infused in immunodeficient tumor bearing mice, human CD44v6.CAR T cells were able to reach, infiltrate and proliferate at tumor sites, finally resulting in tumor growth control. Next, we checked if cells produced in compliance with GMP grade standards retained the same antitumor activity of those produced with research grade materials and protocols. Noteworthy, no differences in the potency of the CAR T obtained with the two manufacturing processes were observed. In conclusion, our preclinical results suggest that CD44v6.CAR T based adoptive therapy could be a promising strategy in solid cancer treatment.
Mechanism of action of the tumor vessel targeting agent NGR-hTNF: Role of both NGR peptide and hTNF in cell binding and signaling
Barbara Valentinis, Simona Porcellini, Claudia Asperti, Manuela Cota, Dan Zhou, Paola Di Matteo, Gianpiero Garau, Chiara Zucchelli, Nilla Roberta Avanzi, Gian Paolo Rizzardi, Massimo Degano, Giovanna Musco, Catia Traversari
International Journal of Molecular Sciences, 2019
NGR-hTNF is a therapeutic agent for a solid tumor that specifically targets angiogenic tumor blood vessels, through the NGR motif. Its activity has been assessed in several clinical studies encompassing tumors of different histological types. The drug’s activity is based on an improved permeabilization of newly formed tumor vasculature, which favors intratumor penetration of chemotherapeutic agents and leukocyte trafficking. This work investigated the binding and the signaling properties of the NGR-hTNF, to elucidate its mechanism of action. The crystal structure of NGR-hTNF and modeling of its interaction with TNFR suggested that the NGR region is available for binding to a specific receptor. Using 2D TR-NOESY experiments, this study confirmed that the NGR-peptides binds to a specific CD13 isoform, whose expression is restricted to tumor vasculature cells, and to some tumor cell lines. The interaction between hTNF or NGR-hTNF with immobilized TNFRs showed similar kinetic parameters, whereas the competition experiments performed on the cells expressing both TNFR and CD13 showed that NGR-hTNF had a higher binding affinity than hTNF. The analysis of the NGR-hTNF-triggered signal transduction events showed a specific impairment in the activation of pro-survival pathways (Ras, Erk and Akt), compared to hTNF. Since a signaling pattern identical to NGR-hTNF was obtained with hTNF and NGR-sequence given as distinct molecules, the inhibition observed on the survival pathways was presumably due to a direct effect of the NGR-CD13 engagement on the TNFR signaling pathway. The reduced activation of the pro survival pathways induced by NGR-hTNF correlated with the increased caspases activation and reduced cell survival. This study demonstrates that the binding of the NGR-motif to CD13 determines not only the homing of NGR-hTNF to tumor vessels, but also the increase in its antiangiogenic activity.
Succinimide-Based Conjugates Improve IsoDGR Cyclopeptide Affinity to αvβ3 without Promoting Integrin Allosteric Activation
Francesca Nardelli, Cristina Paissoni, Giacomo Quilici, Alessandro Gori, Catia Traversari, Barbara Valentinis, Angelina Sacchi, Angelo Corti, Flavio Curnis, Michela Ghitti, Giovanna Musco
Journal of Medicinal Chemistry, 2018
The isoDGR sequence is an integrin-binding motif that has been successfully employed as a tumor-vasculature-homing molecule or for the targeted delivery of drugs and diagnostic agents to tumors. In this context, we previously demonstrated that cyclopeptide 2, the product of the conjugation of c(CGisoDGRG) (1) to 4-( N-maleimidomethyl)cyclohexane-1-carboxamide, can be successfully used as a tumor-homing ligand for nanodrug delivery to neoplastic tissues. Here, combining NMR, computational, and biochemical methods, we show that the succinimide ring contained in 2 contributes to stabilizing interactions with αvβ3, an integrin overexpressed in the tumor vasculature. Furthermore, we demonstrate that various cyclopeptides containing the isoDGR sequence embedded in different molecular scaffolds do not induce αvβ3 allosteric activation and work as pure integrin antagonists. These results could be profitably exploited for the rational design of novel isoDGR-based ligands and tumor-targeting molecules with improved αvβ3-binding properties and devoid of adverse integrin-activating effects.
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Margherita Norelli, Barbara Camisa, Giulia Barbiera, Laura Falcone, Ayurzana Purevdorj, Marco Genua, Francesca Sanvito, Maurilio Ponzoni, Claudio Doglioni, Patrizia Cristofori, Catia Traversari, Claudio Bordignon, Fabio Ciceri, Renato Ostuni, Chiara Bonini, Monica Casucci, Attilio Bondanza
Nature Medicine, 2018
Extracellular NGFR spacers allow efficient tracking and enrichment of fully functional car-t cells co-expressing a suicide gene
Monica Casucci, Laura Falcone, Barbara Camisa, Margherita Norelli, Simona Porcellini, Anna Stornaiuolo, Fabio Ciceri, Catia Traversari, Claudio Bordignon, Chiara Bonini, Attilio Bondanza
Frontiers in Immunology, 2018
Chimeric antigen receptor (CAR)-T cell immunotherapy is at the forefront of innovative cancer therapeutics. However, lack of standardization of cellular products within the same clinical trial and lack of harmonization between different trials have hindered the clear identification of efficacy and safety determinants that should be unveiled in order to advance the field. With the aim of facilitating the isolation and in vivo tracking of CAR-T cells, we here propose the inclusion within the CAR molecule of a novel extracellular spacer based on the low-affinity nerve-growth-factor receptor (NGFR). We screened four different spacer designs using as target antigen the CD44 isoform variant 6 (CD44v6). We successfully generated NGFR-spaced CD44v6 CAR-T cells that could be efficiently enriched with clinical-grade immuno-magnetic beads without negative consequences on subsequent expansion, immuno-phenotype, in vitro antitumor reactivity, and conditional ablation when co-expressing a suicide gene. Most importantly, these cells could be tracked with anti-NGFR monoclonal antibodies in NSG mice, where they expanded, persisted, and exerted potent antitumor effects against both high leukemia and myeloma burdens. Similar results were obtained with NGFR-enriched CAR-T cells specific for CD19 or CEA, suggesting the universality of this strategy. In conclusion, we have demonstrated that the incorporation of the NGFR marker gene within the CAR sequence allows for a single molecule to simultaneously work as a therapeutic and selection/tracking gene. Looking ahead, NGFR spacer enrichment might allow good manufacturing procedures-manufacturing of standardized CAR-T cell products with high therapeutic potential, which could be harmonized in different clinical trials and used in combination with a suicide gene for future application in the allogeneic setting.
The administration of drugs inhibiting cholesterol/oxysterol synthesis is safe and increases the efficacy of immunotherapeutic regimens in tumor-bearing mice
Claudia Lanterna, Andrea Musumeci, Laura Raccosta, Gianfranca Corna, Marta Moresco, Daniela Maggioni, Raffaella Fontana, Claudio Doglioni, Claudio Bordignon, Catia Traversari, Vincenzo Russo
Cancer Immunology Immunotherapy, 2016
24-hydroxycholesterol participates in pancreatic neuroendocrine tumor development
Matias Soncini, Gianfranca Corna, Marta Moresco, Nadia Coltella, Umberto Restuccia, Daniela Maggioni, Laura Raccosta, Chin-Yo Lin, Francesca Invernizzi, Roberto Crocchiolo, Claudio Doglioni, Catia Traversari, Angela Bachi, Rosa Bernardi, Claudio Bordignon, Jan-Åke Gustafsson, Vincenzo Russo
Proceedings of the National Academy of Sciences of the United States of America, 2016
T cells as antigen carriers for anti-tumor vaccination
Catia Traversari, Vincenzo Russo
Methods in Molecular Biology, 2016
Erratum: Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory (Science Translational Medicine (2015) 7:319 (319er9))
G. Oliveira, E. Ruggiero, M. Stanghellini, N. Cieri, M. D'Agostino, R. Fronza, Christina Lulay, F. Dionisio, S. Mastaglio, R. Greco, J. Peccatori, A. Aiuti, A. Ambrosi, L. Biasco, A. Bondanza, A. Lambiase, C. Traversari, L. Vago, C. Kalle, M. Schmidt, C. Bordignon, F. Ciceri, C. Bonini
Science Translational Medicine, 2015
Tracking genetically engineered lymphocytes long-term reveals the dynamics of t cell immunological memory
Giacomo Oliveira, Eliana Ruggiero, Maria Teresa Lupo Stanghellini, Nicoletta Cieri, Mattia D’Agostino, Raffaele Fronza, Christina Lulay, Francesca Dionisio, Sara Mastaglio, Raffaella Greco, Jacopo Peccatori, Alessandro Aiuti, Alessandro Ambrosi, Luca Biasco, Attilio Bondanza, Antonio Lambiase, Catia Traversari, Luca Vago, Christof von Kalle, Manfred Schmidt, Claudio Bordignon, Fabio Ciceri, Chiara Bonini
Science Translational Medicine, 2015
The tumor vessel targeting agent NGR-TNF controls the different stages of the tumorigenic process in transgenic mice by distinct mechanisms
Simona Porcellini, Claudia Asperti, Barbara Valentinis, Elena Tiziano, Patrizia Mangia, Claudio Bordignon, Gian-Paolo Rizzardi, Catia Traversari
Oncoimmunology, 2015
Haploidentical HSCT: A 15-year experience at San Raffaele
C Bonini, J Peccatori, M T L Stanghellini, L Vago, A Bondanza, N Cieri, R Greco, M Bernardi, C Corti, G Oliveira, E Zappone, C Traversari, C Bordignon, F Ciceri
Bone Marrow Transplantation, 2015
Anti-metastatic activity of the tumor vascular targeting agent NGR-TNF
Paola Di Matteo, Patrizia Mangia, Elena Tiziano, Barbara Valentinis, Simona Porcellini, Claudio Doglioni, Francesca Sanvito, Claudio Bordignon, Gian-Paolo Rizzardi, Catia Traversari
Clinical and Experimental Metastasis, 2015
LXR-dependent and -independent effects of oxysterols on immunity and tumor growth
Catia Traversari, Silvano Sozzani, Knut R. Steffensen, Vincenzo Russo
European Journal of Immunology, 2014
Oxysterols recruit tumor-supporting neutrophils within the tumor microenvironment: The many facets of tumor-derived oxysterols
Laura Raccosta, Raffaella Fontana, Catia Traversari, Vincenzo Russo
Oncoimmunology, 2013
The oxysterol-cxcr2 axis plays a key role in the recruitment of tumor-promoting neutrophils
Laura Raccosta, Raffaella Fontana, Daniela Maggioni, Claudia Lanterna, Eduardo J. Villablanca, Aida Paniccia, Andrea Musumeci, Elena Chiricozzi, Maria Letizia Trincavelli, Simona Daniele, Claudia Martini, Jan-Ake Gustafsson, Claudio Doglioni, Safiyè Gonzalvo Feo, Andrea Leiva, Maria Grazia Ciampa, Laura Mauri, Cristina Sensi, Alessandro Prinetti, Ivano Eberini, J. Rodrigo Mora, Claudio Bordignon, Knut R. Steffensen, Sandro Sonnino, Silvano Sozzani, Catia Traversari, Vincenzo Russo
Journal of Experimental Medicine, 2013
NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells
P Di Matteo, C Hackl, C Jedeszko, B Valentinis, C Bordignon, C Traversari, R S Kerbel, G-P Rizzardi
British Journal of Cancer, 2013
Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes
Vincenzo Russo, Lorenzo Pilla, Francesca Lunghi, Roberto Crocchiolo, Raffaella Greco, Fabio Ciceri, Daniela Maggioni, Raffaella Fontana, Sylvain Mukenge, Licia Rivoltini, Gianluigi Rigamonti, Santo Raffaele Mercuri, Roberto Nicoletti, Alessandro Del Maschio, Luigi Gianolli, Ferruccio Fazio, Alfonso Marchianò, Annabella Di Florio, Michele Maio, Monica Salomoni, Corrado Gallo-Stampino, Matteo Del Fiacco, Antonio Lambiase, Pierre G. Coulie, Roberto Patuzzo, Giorgio Parmiani, Catia Traversari, Claudio Bordignon, Mario Santinami, Marco Bregni
International Journal of Cancer, 2013
De Novo design of a tumor-penetrating peptide
Luca Alberici, Lise Roth, Kazuki N. Sugahara, Lilach Agemy, Venkata R. Kotamraju, Tambet Teesalu, Claudio Bordignon, Catia Traversari, Gian-Paolo Rizzardi, Erkki Ruoslahti
Cancer Research, 2013
T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation
Luca Vago, Giacomo Oliveira, Attilio Bondanza, Maddalena Noviello, Corrado Soldati, Domenico Ghio, Immacolata Brigida, Raffaella Greco, Maria Teresa Lupo Stanghellini, Jacopo Peccatori, Sergio Fracchia, Matteo Del Fiacco, Catia Traversari, Alessandro Aiuti, Alessandro Del Maschio, Claudio Bordignon, Fabio Ciceri, Chiara Bonini
Blood, 2012
Molecular dynamics reveal that isoDGR-containing cyclopeptides are true αvβ3 antagonists unable to promote integrin allostery and activation
Michela Ghitti, Andrea Spitaleri, Barbara Valentinis, Silvia Mari, Claudia Asperti, Catia Traversari, Gian Paolo Rizzardi, Giovanna Musco
Angewandte Chemie International Edition, 2012
A dual role for genetically modified lymphocytes in cancer immunotherapy
Vincenzo Russo, Attilio Bondanza, Fabio Ciceri, Marco Bregni, Claudio Bordignon, Catia Traversari, Chiara Bonini
Trends in Molecular Medicine, 2012
Control of the immune system by oxysterols and cancer development
Catia Traversari, Vincenzo Russo
Current Opinion in Pharmacology, 2012
Thymidine kinase suicide gene-mediated ganciclovir ablation of autologous gene-modified rhesus hematopoiesis
Cecilia N Barese, Allen E Krouse, Mark E Metzger, Connor A King, Catia Traversari, Frank C Marini, Robert E Donahue, Cynthia E Dunbar
Molecular Therapy, 2012
Use of metadynamics in the design of isoDGR-based αvβ3 antagonists to fine-tune the conformational ensemble
Andrea Spitaleri, Michela Ghitti, Silvia Mari, Luca Alberici, Catia Traversari, Gian‐Paolo Rizzardi, Giovanna Musco
Angewandte Chemie International Edition, 2011
Enhanced expression of CD13 in vessels of inflammatory and neoplastic tissues
Paola Di Matteo, Gian Luigi Arrigoni, Luca Alberici, Angelo Corti, Corrado Gallo-Stampino, Catia Traversari, Claudio Doglioni, Gian-Paolo Rizzardi
Journal of Histochemistry and Cytochemistry, 2011
An efficient strategy to induce and maintain in vitro human T cells specific for autologous Non-Small Cell Lung Carcinoma
Glenda Canderan, Paola Gruarin, Daniela Montagna, Raffaella Fontana, Giulio Melloni, Catia Traversari, Paolo Dellabona, Giulia Casorati
Plos One, 2010
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy
Armando Santoro, Lorenza Rimassa, Alberto F. Sobrero, Giovanni Citterio, Francesco Sclafani, Carlo Carnaghi, Anna Pessino, Francesco Caprioni, Valeria Andretta, Maria Chiara Tronconi, Giovanna Finocchiaro, Gloria Rossoni, Angela Zanoni, Chiara Miggiano, Gian-Paolo Rizzardi, Catia Traversari, Federico Caligaris-Cappio, Antonio Lambiase, Claudio Bordignon
European Journal of Cancer, 2010
Critical role of flanking residues in NGR-to-isoDGR transition and CD13/integrin receptor switching
Flavio Curnis, Angela Cattaneo, Renato Longhi, Angelina Sacchi, Anna Maria Gasparri, Fabio Pastorino, Paola Di Matteo, Catia Traversari, Angela Bachi, Mirco Ponzoni, Gian-Paolo Rizzardi, Angelo Corti
Journal of Biological Chemistry, 2010
2D TR-NOESY experiments interrogate and rank ligand-receptor interactions in living human cancer cells
Silvia Mari, Chiara Invernizzi, Andrea Spitaleri, Luca Alberici, Michela Ghitti, Claudio Bordignon, Catia Traversari, Gian‐Paolo Rizzardi, Giovanna Musco
Angewandte Chemie International Edition, 2010
Tumor-mediated liver X receptor-α activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses
Eduardo J Villablanca, Laura Raccosta, Dan Zhou, Raffaella Fontana, Daniela Maggioni, Aurora Negro, Francesca Sanvito, Maurilio Ponzoni, Barbara Valentinis, Marco Bregni, Alessandro Prinetti, Knut R Steffensen, Sandro Sonnino, Jan-Ake Gustafsson, Claudio Doglioni, Claudio Bordignon, Catia Traversari, Vincenzo Russo
Nature Medicine, 2010
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study
Fabio Ciceri, Chiara Bonini, Maria Teresa Lupo Stanghellini, Attilio Bondanza, Catia Traversari, Monica Salomoni, Lucia Turchetto, Scialini Colombi, Massimo Bernardi, Jacopo Peccatori, Alessandra Pescarollo, Paolo Servida, Zulma Magnani, Serena K Perna, Veronica Valtolina, Fulvio Crippa, Luciano Callegaro, Elena Spoldi, Roberto Crocchiolo, Katharina Fleischhauer, Maurilio Ponzoni, Luca Vago, Silvano Rossini, Armando Santoro, Elisabetta Todisco, Jane Apperley, Eduardo Olavarria, Shimon Slavin, Eva M Weissinger, Arnold Ganser, Michael Stadler, Evangelia Yannaki, Athanasios Fassas, Achilles Anagnostopoulos, Marco Bregni, Corrado Gallo Stampino, Paolo Bruzzi, Claudio Bordignon
Lancet Oncology, 2009
Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients
Raffaella Fontana, Marco Bregni, Arcadi Cipponi, Laura Raccosta, Cristina Rainelli, Daniela Maggioni, Francesca Lunghi, Fabio Ciceri, Sylvain Mukenge, Claudio Doglioni, Didier Colau, Pierre G. Coulie, Claudio Bordignon, Catia Traversari, Vincenzo Russo
Blood, 2009
IL-7 and IL-15 allow the generation of suicide gene modified alloreactive self-renewing central memory human T lymphocytes
Shin Kaneko, Sara Mastaglio, Attilio Bondanza, Maurilio Ponzoni, Francesca Sanvito, Luca Aldrighetti, Marina Radrizzani, Simona La Seta-Catamancio, Elena Provasi, Anna Mondino, Toshiro Nagasawa, Katharina Fleischhauer, Vincenzo Russo, Catia Traversari, Fabio Ciceri, Claudio Bordignon, Chiara Bonini
Blood, 2009
Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFNγ
Anna Maria Gasparri, Elena Jachetti, Barbara Colombo, Angelina Sacchi, Flavio Curnis, Gian-Paolo Rizzardi, Catia Traversari, Matteo Bellone, Angelo Corti
Molecular Cancer Therapeutics, 2008
Isoaspartate-glycine-arginine: A new tumor vasculature-targeting motif
Flavio Curnis, Angelina Sacchi, Anna Gasparri, Renato Longhi, Angela Bachi, Claudio Doglioni, Claudio Bordignon, Catia Traversari, Gian-Paolo Rizzardi, Angelo Corti
Cancer Research, 2008
Selected natural and synthetic retinoids impair CCR7- and CXCR4-dependent cell migration in vitro and in vivo
Eduardo J Villablanca, Dan Zhou, Barbara Valentinis, Aurora Negro, Laura Raccosta, Laura Mauri, Alessandro Prinetti, Sandro Sonnino, Claudio Bordignon, Catia Traversari, Vincenzo Russo
Journal of Leukocyte Biology, 2008
Structural basis for the interaction of isoDGR with the RGD-binding site of αvβ3 integrin
Andrea Spitaleri, Silvia Mari, Flavio Curnis, Catia Traversari, Renato Longhi, Claudio Bordignon, Angelo Corti, Gian-Paolo Rizzardi, Giovanna Musco
Journal of Biological Chemistry, 2008
Human recombinant heat shock protein 70 affects the maturation pathways of dendritic cells in vitro and has an in vivo adjuvant activity
Barbara Valentinis, Annalisa Capobianco, Francesca Esposito, Alessandro Bianchi, Patrizia Rovere-Querini, Angelo A Manfredi, Catia Traversari
Journal of Leukocyte Biology, 2008
Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity
Vincenzo Russo, Arcadi Cipponi, Laura Raccosta, Cristina Rainelli, Raffaella Fontana, Daniela Maggioni, Francesca Lunghi, Sylvain Mukenge, Fabio Ciceri, Marco Bregni, Claudio Bordignon, Catia Traversari
Journal of Clinical Investigation, 2007
Abrogation of prostaglandin E2/EP4 signaling impairs the development of rag1+ lymphoid precursors in the thymus of zebrafish embryos
Eduardo J Villablanca, Anna Pistocchi, Felipe A Court, Franco Cotelli, Claudio Bordignon, Miguel L Allende, Catia Traversari, Vincenzo Russo
Journal of Immunology, 2007
CD8+ T lymphocytes isolated from renal cancer patients recognize tumour cells through an HLA- and TCR/CD3-independent pathway
Ilaria Lionello, Patrizia Mangia, Luca Gattinoni, Daniela Pende, Arcadi Cippone, Marialuisa Sensi, Patrizio Rigatti, Catia Traversari
Cancer Immunology Immunotherapy, 2007
The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies
Catia Traversari, Sarah Marktel, Zulma Magnani, Patrizia Mangia, Vincenzo Russo, Fabio Ciceri, Chiara Bonini, Claudio Bordignon
Blood, 2007
Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation
Fabio Ciceri, Chiara Bonini, Sarah Marktel, Elisabetta Zappone, Paolo Servida, Massimo Bernardi, Alessandra Pescarollo, Attilio Bondanza, Jacopo Peccatori, Silvano Rossini, Zulma Magnani, Monica Salomoni, Claudia Benati, Maurilio Ponzoni, Luciano Callegaro, Paolo Corradini, Marco Bregni, Catia Traversari, Claudio Bordignon
Blood, 2007
The suicide gene therapy challenge: How to improve a successful gene therapy approach
Chiara Bonini, Attilio Bondanza, Serena Kimi Perna, Shin Kaneko, Catia Traversari, Fabio Ciceri, Claudio Bordignon
Molecular Therapy, 2007
Generation of tumour-specific cytotoxic T-cell clones from histocompatibility leucocyte antigen-identical siblings of patients with melanoma
D J Gottlieb, Y-C Li, I Lionello, S Tanzarella, M Marangolo, K F Bradstock, V Russo, C Traversari
British Journal of Cancer, 2006
Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes
Attilio Bondanza, Veronica Valtolina, Zulma Magnani, Maurilio Ponzoni, Katharina Fleischhauer, Mark Bonyhadi, Catia Traversari, Francesca Sanvito, Salvatore Toma, Marina Radrizzani, Simona La Seta-Catamancio, Fabio Ciceri, Claudio Bordignon, Chiara Bonini
Blood, 2006
An anti-CD45RO/RB monoclonal antibody modulates T cell responses via induction of apoptosis and generation of regulatory T cells
Silvia Gregori, Patrizia Mangia, Rosa Bacchetta, Eleonora Tresoldi, Frank Kolbinger, Catia Traversari, Josè M. Carballido, Jan E. de Vries, Ulf Korthäuer, Maria-Grazia Roncarolo
Journal of Experimental Medicine, 2005
Direct effects of polymyxin B on human dendritic cells maturation: The role of IκB-α/NF-κB and ERK1/2 pathways and adhesion
Barbara Valentinis, Alessandro Bianchi, Dan Zhou, Arcadi Cipponi, Federica Catalanotti, Vincenzo Russo, Catia Traversari
Journal of Biological Chemistry, 2005
Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-Aza-2′-deoxycytidine
Luca Sigalotti, Elisabetta Fratta, Sandra Coral, Silvia Tanzarella, Riccardo Danielli, Francesca Colizzi, Ester Fonsatti, Catia Traversari, Maresa Altomonte, Michele Maio
Cancer Research, 2004
HMGB1 is an endogenous immune adjuvant released by necrotic cells
Patrizia Rovere‐Querini, Annalisa Capobianco, Paola Scaffidi, Barbara Valentinis, Federica Catalanotti, Marta Giazzon, Ingrid E Dumitriu, Susanne Müller, Matteo Iannacone, Catia Traversari, Marco E Bianchi, Angelo A Manfredi
EMBO Reports, 2004
Prognostic significance of cancer-testis gene expression in resected non-small cell lung cancer patients
Oncology Reports, 2004
Rhabdomyosarcomas are potential target of MAGE-specific immunotherapies
Barbara Valentinis, Catia Traversari, Silvia Tanzarella, Ilaria Lionello, Vincenzo Russo, Pier-Luigi Lollini
Cancer Immunology Immunotherapy, 2004
Multiple mechanisms are responsible for the alteration in the expression of HLA class I antigens in melanoma [2]
Francisco Ruiz‐Cabello, Catia Traversari, Federico Garrido
International Journal of Cancer, 2003
Safety of retroviral gene marking with a truncated NGF receptor [1]
C. Bonini, M. Grez, C. Traversari, F. Ciceri, S. Marktel, G. Ferrari, M. Dinauer, M. Sadat, A. Aiuti, S. Deola, M. Radrizzani, A. Hagenbeek, J. Apperley, S. Ebeling, A. Martens, H.J. Kolb, M. Weber, F. Lotti, A. Grande, E. Weissinger, J.A. Bueren, M. Lamana, J.H.F. Falkenburg, M.H.M. Heemskerk, T. Austin, S. Kornblau, F. Marini, C. Benati, Z. Magnani, S. Cazzaniga, S. Toma, C. Gallo-Stampino, M. Introna, S. Slavin, P.D. Greenberg, M. Bregni, F. Mavilio, C. Bordignon
Nature Medicine, 2003
Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation
Sarah Marktel, Zulma Magnani, Fabio Ciceri, Sabrina Cazzaniga, Stanley R. Riddell, Catia Traversari, Claudio Bordignon, Chiara Bonini
Blood, 2003
Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3
Giuseppe Consogno, Simona Manici, Valeria Facchinetti, Angela Bachi, Juergen Hammer, Bianca M. Conti-Fine, Claudio Rugarli, Catia Traversari, Maria Pia Protti
Blood, 2003
Expression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′-deoxycytidine treatment
Alfonso Serrano, Silvia Tanzarella, Ilaria Lionello, Rosa Mendez, Catia Traversari, Francisco Ruiz-Cabello, Federico Garrido
International Journal of Cancer, 2001
A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes
E.S. Schultz, Y. Zhang, R. Knowles, J. Tine, C. Traversari, T. Boon, P. Van Der Bruggen
Tissue Antigens, 2001
A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease
Daniel C. Thomis, Sarah Marktel, Chiara Bonini, Catia Traversari, Michael Gilman, Claudio Bordignon, Tim Clackson
Blood, 2001
Differentiation of T regulatory cells by immature dendritic cells
Maria-Grazia Roncarolo, Megan K. Levings, Catia Traversari
Journal of Experimental Medicine, 2001
Various cells retrovirally transduced with N-acetylgalactosoamine-6-sulfate sulfatase correct Morquio skin fibroblasts in vitro
Gabriele Toietta, Giovanni Maria Severini, Catia Traversari, Shunji Tomatsu, Kazuko Sukegawa, Seiji Fukuda, Naomi Kondo, Paolo Tortora, Claudio Bordignon
Human Gene Therapy, 2001
Identification of tumor antigen-specific cytotoxic T lymphocytes cross-recognizing allogeneic major histocompatibility class I molecules
K. Fleischhauer, L. Gattinoni, G. Lietti, E. Zino, C. Bordignon, C. Traversari
Tissue Antigens, 2000
Acquisition of intact allogeneic human leukocyte antigen molecules by human dendritic cells
Vincenzo Russo, Dan Zhou, Claudia Sartirana, Patrizia Rovere, Antonello Villa, Silvano Rossini, Catia Traversari, Claudio Bordignon
Blood, 2000
Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response
Vincenzo Russo, Silvia Tanzarella, Piero Dalerba, Donata Rigatti, Patrizia Rovere, Antonello Villa, Claudio Bordignon, Catia Traversari
Proceedings of the National Academy of Sciences of the United States of America, 2000
Tumor-antigens recognised by T lymphocytes
Minerva Biotecnologica, 1999
Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1
Journal of Immunology, 1999
Identification of a promiscuous T-cell epitope encoded by multiple members of the mage family
Cancer Research, 1999
Major histocompatibility complex class I restricted cytotoxic T cells specific for natural melanoma peptides recognize unidentified shared melanoma antigen(s)
Cancer Research, 1999
Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: Clinical follow-up and improved new vectors
Simona Verzeletti, Chiara Bonini, Sarah Marktel, Nadia Nobili, Fabio Ciceri, Catia Traversari, Claudio Bordignon
Human Gene Therapy, 1998
Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage
Raffaella Lupetti, Patrizia Pisarra, Alessandro Verrecchia, Cinthia Farina, Gabriella Nicolini, Andrea Anichini, Claudio Bordignon, Marialuisa Sensi, Giorgio Parmiani, Catia Traversari
Journal of Experimental Medicine, 1998
The DAM gene family encodes a new group of tumor-specific antigens recognized by human leukocyte antigen A2-restricted cytotoxic T lymphocytes
Cancer Research, 1998
High homogeneity of mage, bage, gage, tyrosinase and Melan-A/Mart-1 gene expression in clusters of multiple simultaneous metastases of human melanoma: Implications for protocol design of therapeutic antigen-specific vaccination strategies
Piero Dalerba, Axel Ricci, Vincenzo Russo, Donata Rigatti, Maria Rita Nicotra, Marcella Mottolese, Claudio Bordignon, Pier Giorgio Natali, Catia Traversari
International Journal of Cancer, 1998
Gene therapy of lymphoid tumors
Minerva Biotecnologica, 1997
Functional heterogeneity of HLA-A*02 subtypes revealed by presentation of a MAGE-3-encoded peptide to cytotoxic T cell clones
Journal of Immunology, 1997
Characterization of antigenic peptide epitopes by reverse immunology: Induction of cytotoxic T lymphocytes specific for exogenous peptide only [1]
Silvia Tanzarella, Katharina Fleischhauer, Peter van Endert, Claudio Bordignon, Catia Traversari
International Journal of Cancer, 1997
HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia
Chiara Bonini, Giuliana Ferrari, Simona Verzeletti, Paolo Servida, Elisabetta Zappone, Luciano Ruggieri, Maurilio Ponzoni, Silvano Rossini, Fulvio Mavilio, Catia Traversari, Claudio Bordignon
Science, 1997
IFN-γ gene transfer restores HLA-class I expression and MAGE-3 antigen presentation to CTL in HLA-deficient small cell lung cancer
C Traversari, R Meazza, M Coppolecchia, S Basso, A Verrecchia, P van der Bruggen, A Ardizzoni, A Gaggero, S Ferrini
Gene Therapy, 1997
Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3
Katharina Fleischhauer, Doriana Fruci, Peter van Endert, Jean Herman, Silvia Tanzarella, Hans-J. Wallny, Pierre Coulie, Claudio Bordignon, Catia Traversari
International Journal of Cancer, 1996
Multiple Melanoma-Associated Epitopes Recognized by HLA-A3-Restricted CTLs and Shared by Melanomas but Not Melanocytes
Journal of Immunology, 1996
Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*0201+ cytotoxic T cell line
Journal of Immunology, 1996
MAGE BAGE and GAGE genes expression in fresh epithelial ovarian carcinomas.
Vincenzo Russo, Piero Dalerba, Axel Ricci, Cristina Bonazzi, B. E. Leone, Costantino Mangioni, Paola Allavena, Claudio Bordignon, Catia Traversari
International Journal of Cancer Journal International Du Cancer, 1996
Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1
Proceedings of the National Academy of Sciences of the United States of America, 1995
Expression of the mage gene family in primary and metastatic human breast cancer: Implications for tumor antigen‐specific immunotherapy
Vincenzo Russo, Catia Traversari, Alessandro Verrecchia, Marcella Mottolese, Pier Giorgio Natali, Claudio Bordignon
International Journal of Cancer, 1995
A family of rapidly evolving genes from the sex reversal critical region in Xp21
B. Dabovic, E. Zanaria, B. Bardoni, A. Lisa, C. Bordignon, V. Russo, C. Matessi, C. Traversari, G. Camerino
Mammalian Genome, 1995
Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation
Human Gene Therapy, 1995
Structure, chromosomal localization, and expression of 12 genes of the MAGE family
Etienne De Plaen, Catia Traversari, José J. Gaforio, Jean-Pierre Szikora, Charles De Smet, Francis Brasseur, Pierre van der Bruggen, Bernard Lethé, Christophe Lurquin, Patrick Chomez, Olivier De Backer, Thierry Boon, Karen Arden, Webster Cavenee, Robert Brasseur
Immunogenetics, 1994
A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
P G Coulie, V Brichard, A Van Pel, T Wölfel, J Schneider, C Traversari, S Mattei, E De Plaen, C Lurquin, J P Szikora, J C Renauld, T Boon
Journal of Experimental Medicine, 1994
Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer
F Mavilio, G Ferrari, S Rossini, N Nobili, C Bonini, G Casorati, C Traversari, C Bordignon
Blood, 1994
Characterization of natural peptide ligands for HLA‐B*4402 and ‐B*4403: implications for peptide involvement in allorecognition of a single amino acid change in the HLA‐B44 heavy chain
K. Fleischhauer, D. Avila, F. Vilbois, C. Traversari, C. Bordignon, H.‐J. Wallny
Tissue Antigens, 1994
A peptide encoded by human gene MAGE‐3 and presented by HLA‐A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE‐3
Pierre van der Bruggen, Judy Bastin, Thomas Gajewski, Pierre G. Coulie, Pascale Boël, Charles De Smet, Catia Traversari, Alain Townsend, Thierry Boon
European Journal of Immunology, 1994
A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E
Journal of Experimental Medicine, 1992
Involvement of somatically acquired ecotropic viruses in the immunogenicity of nude-transplanted NIH/3T3 transformed cell lines
Journal of Immunology, 1992
Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes
Catia Traversari, Pierre van der Bruggen, Benoît Van den Eynde, Philippe Hainaut, Carine Lemoine, Nobuyoshi Ohta, Lloyd Old, Thierry Boon
Immunogenetics, 1992
Identification of tumour rejection antigens recognized by T lymphocytes
Cancer Surveys, 1992
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
P. van der Bruggen, C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, T. Boon
Science, 1991
Ultrastructural cytoskeleton alterations and modification of actin expression in the NIH/3T3 cell line after transformation with ha-ras-activated oncogene
Luciano Lombardi, Dario Ballinari, Italia Bongarzone, Marco Migliari, Piera Mondellini, Catia Traversai, Silvia Modina
Cell Motility and the Cytoskeleton, 1990
Expression of retrovirus-related, cytotoxic T lymphocyte- and transplantation-defined antigens in NIH/3T3 transfectants after a single passage in nude mice
Journal of Immunology, 1989
Early lymphocyte activation molecule defined by the monoclonal antibody MLR-3: Biochemical and functional studies
Immunology, 1988
Modulation of the human Harvey-ras oncogene expression by DNA methylation
Oncogene Research, 1988
Monoclonal antibodies against NIH 3T3 cells transformed by human thyroid carcinoma DNA
RACHELE ALZANI, MARCO A. PIEROTTI, SYLVIE MÉNARD, SILVANA CANEVARI, MARIA L. FERTONANI, DARIO BALLINARI, CATIA TRAVERSARI, GABRIELLA DELLA TORRE, PAOLO RADICE, SILVANA PILOTTI, ALFREDO FUSCO, MICHELE GRIECO, GIUSEPPE DELLA PORTA, MARIA I. COLNAGHI
Hybridoma, 1988
Ly-5.185 molecule is associated with thymic maturation of lymphocytes but not with their cytotoxic activity
Experimental and Clinical Immunogenetics, 1987
Disulfide‐linked surface molecules of monoclonal antigen‐specific suppressor T cells: evidence for T cell receptor structures
Dario Ballinari, Chiara Castelli, Catia Traversari, Marco A. Pierotti, Giorgio Parmiani, Gabriella Palmieri, Paola Ricciardi‐Castagnoli, Luciano Adorini
European Journal of Immunology, 1985
Ly-5 molecular forms in congenitally immunodeficient mice
Experimental and Clinical Immunogenetics, 1984

Catia Traversari

RESEARCH INTERESTS

Scopus Publications